




***31° Residential Course***  
**Modern Radiotherapy, innovative treatments**  
**and patient compliance**

**12 November 2021 - virtual**  
**22, 23 November 2021 – onsite, live streaming**  
**26 November 2021 - virtual**

**Scientific Coordinators:** V. Valentini, M.A. Gambacorta, L. Indovina  
**Honorary Presidents:** C.A. Perez, N. Cellini



**12 November 2021  
(VIRTUAL)**

16.00-16.05    Opening: course aims and modalities

V.Valentini, M.A.Gambacorta

16.05-16.15	What is considered compliance in the 20's?	M.A. Gambacorta
-------------	--	-----------------

**Opening lecture (recorded)**

16.15-16.40	Omics sciences and compliance to radiotherapy: is there a link?	A. Chalmers
-------------	---	-------------

**Session 1 (live)**

**Metrics: Which compliance to be measured?**

16.40-16.55	...in radiotherapy randomized trials. The clinical perspective	P. Hoskin
16.55-17.10	...in radiotherapy randomized trials. The dosimetric perspective	D. Verellen
17.10-17.25	...in technical innovations. The clinical perspective	B. Jereczek
17.25-17.40	...in technical innovations. The dosimetric perspective	U. van der Heide

17.40-17.55    Question time

**17.55-18.10 Break**

**Laboratory 1 (live)**

18.10-18.55	PROM, PREM, App and IOT
-------------	-------------------------

**22 November 2021  
(ONSITE and LIVE STREAMING)**

**Session 2 (live)**

**Metrics: which compliance is important for the patient undergoing radiotherapy?**

09.00-09.15	Treatment compliance: patients vs clinicians perspectives	P. Hoskin
09.15-09.30	Treatment compliance: the psychological dimension in adults	L. Dinapoli
09.30-09.45	Treatment compliance: priorities of care in elderly	G.F. Colloca
09.45-10.00	Treatment compliance: the relational dimension in paediatrics	E. Marconi

10.00-10.15 Question time

**10.15-10.30 Break**

**Session 3 (live)**

**Actions: How to prevent and recover no-compliance?**

10.30-10.45	Recommendations for no-compliance in radiotherapy treatments	K. Haustermans
10.45-11.00	Recommendations for no-compliance in chemoradiotherapy treatments	E. Fokas
11.00-11.15	Innovation: AI and error prevention in RT	D. Verellen
11.15-11.30	Innovation: nutritional aspects and microbioma	A. Gasbarrini

11.30-11.45 Question time

**Lecture 1 (live or recorded)**

11.45-12.10	Image guided radiotherapy technologies and treatment compliance	B. Slotman
-------------	---	------------

**Laboratory 2 (live)**

12.10-12.55	Virtual coaching during innovative oncology treatments
-------------	--

**12.55-14.30 Lunch Break**

**Session 4 (live)**

**Actions: Will innovation change compliance in radiotherapy treatments?**

14.30-14.45	Innovation in image guided external beam radiotherapy	U. van der Heide
14.45-15.00	Innovation in adaptive external beam radiotherapy	S. Corradini
15.00-15.15	Innovation in interventional radiotherapy	L. Tagliaferri
15.15-15.30	Innovation in particle therapies external beam radiotherapy	A. Hoffman

15.30-15.45 Question time

**15.45-16.00 Break**

## Lecture 2 (live or recorded)

16.00-16.25	What is considered innovation in 20's radiotherapy?	A. Kirby
-------------	---	----------

## Session 5 (live)

**Actions: Big Data and AI: which contribution to compliance?**

16.25-16.40	Big Data and AI for compliance monitoring clinical meaning	C. Faivre-Finn
16.40-16.55	Big Data and AI for compliance prediction	A. Dekker
16.55-17.10	Art and AI for patient's resilience	V. Valentini

17.10-17.25 Question time

## Lecture 3 (live or recorded)

17.45 -18.10	Compliance to treatments using stereotactic technologies	M. Guckenberger
--------------	--	-----------------

**23 November 2021**  
**(ONSITE and LIVE STREAMING)**

**Lecture 4 (live or recorded)**

09.00-09.25	FLASH therapy and compliance: a new era?	J. Bourhis
-------------	--	------------

**Session 6 (live)**

**Actions: Does drug innovation change compliance in combined treatments?**

09.25-09.40	Monoclonal antibodies and small molecules	E. Fokas
09.40-09.55	Immune check point blockade	M. De Joong
09.55-10.10	Androgen pathway therapy	S. Arcangeli

10.10-10.25 Question time

**Lecture 5 (live or recorded)**

10.25-10.50	Immunotherapy and radiotherapy: efficacy, innovative fractionations and compliance	P. Lambin
-------------	--	-----------

**10.50-11.05 Break**

**Session 7 (live)**

**Focus on: Prostate cancer innovation and compliance**

11.05-11.25	Innovation, effectiveness and compliance in prostate cancer	P. Blanchard
11.25-11.40	Constraints and toxicity in standard treatments	B. Jereczek
11.40-11.55	Constraints and toxicity in innovative treatments	N. Jornet

11.55-12.10 Question time

**Session 8 (live)**

**Focus on: H&N cancer innovation and compliance**

12.10-12.30	Innovation, effectiveness and compliance in H&N cancers	V. Grégoire
12.30-12.45	Constraints and toxicity in non conventional fractionations	P. Bonomo
12.45-13.00	Constraints and toxicity in innovative drug combinations	R. Martinez-Monge

13.00-13.15 Question time

**13.15-14.30 Lunch Break**

**Lecture 6 (live)**

14.30-15.00 Sponsored lectures

## Session 9 (live)

### Focus on: Lung cancer innovation and compliance

15.00-15.20	Innovation, effectiveness and compliance in lung cancers	C. Faivre-Finn
15.20-15.35	Constraints and toxicity in standard treatments	S. Ramella
15.35-15.50	Constraints and toxicity in innovative treatments	M. Massaccesi

15.50-16.10 Question time

## Lecture 7 (live or recorded)

16.10-16.30	Compliance between innovation and clinical experience: thoughts of an expert	U. Ricardi
-------------	---	------------

16.30-16.45 Closing remarks

V.Valentini, M.A.Gambacorta

**26 November 2021  
(VIRTUAL)**

**Lecture 8 (live or recorded)**

15.30-15.55	Particle therapy and patient compliance	E. Troost
-------------	---	-----------

**Session 10 (live)**

**Focus on: Breast cancer innovation and compliance**

15.55-16.15	Innovation, effectiveness and compliance in breast cancer	A. Kirby
16.15-16.30	Constraints and toxicity in standard treatments	F. Marazzi
16.30-16.45	Constraints and toxicity in non standard fractionation treatments	I. Meattini

16.45-17.00 Question time

**17.00-17.15 Break**

**Session 11 (live)**

**Focus on: Anal cancer innovation and compliance**

17.15-17.35	Innovation, effectiveness and compliance in anal cancer	K. Haustermans
17.35-17.50	Constraints and toxicity in standard treatments	P.F. Franco
17.50-18.05	Constraints and toxicity in interventional radiotherapy treatments	G. Kovács

18.05-18.20 Question time

18.20 Closing remarks V.Valentini, M.A.Gambacorta